Skip to main content
. 2022 Jun 7;9(4):e200004. doi: 10.1212/NXI.0000000000200004

Figure 3. Ofatumumab Decreases T Cell Reactivity in Patients With MS.

Figure 3

(A) Flow cytometry dot plot examples of IFN-γ, TNFα, GM-CSF, and IL-17 production in T cells stimulated with anti-CD3/CD28 beads. (B.a–d) Frequency of CD4+ T cells producing IFN-γ (B.a), TNFα (B.b), GM-CSF (B.c), and IL-17 (B.d) in response to anti-CD3/CD28 beads in untreated (UNT) and ofatumumab-treated patients with RRMS. (C.a–d) Frequency of CD4+ T cells producing IFN-γ (C.a–b), GM-CSF (C.c), and IL-17 (C.d) in response to myelin basic protein, MBP, or MOG. The mean value is shown for all groups analyzed. MBP = myelin basic protein; MOG = myelin oligodendrocyte glycoprotein; MS = multiple sclerosis; RRMS = relapsing-remitting MS.